Evidence map›Paper›PMID 27315280›Full record

ArticlePloS one2016

Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India.

Kavitha Saravu, Rishikesh Kumar, Herikudru Ashok, Premananda Kundapura, Veena Kamath, Asha Kamath, Chiranjay Mukhopadhyay

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 8 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 8 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. A systematic review of CQ-resistantPathogens and global health · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Frontiers in cellular and infection microbiology · 2025
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. A systematic review and meta-analysis on sub-microscopicThe Lancet regional health. Southeast Asia · 2022
    Article
  18. Simultaneous detection ofFrontiers in genetics · 2022
    Article
  19. Recurrence inF1000Research · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kavitha SaravuDepartment of Medicine, Kasturba Medical College, Manipal University, Madhav Nagar, Manipal, Karnataka, India.
Rishikesh KumarDepartment of Medicine, Kasturba Medical College, Manipal University, Madhav Nagar, Manipal, Karnataka, India.
Herikudru AshokDistrict Health Office, Udupi, Karnataka, India.
Premananda KundapuraDistrict Malaria Office, Udupi, Karnataka, India.
Veena KamathDepartment of Community Medicine, Kasturba Medical College, Manipal University, Madhav Nagar, Manipal, India.
Asha KamathDepartment of Community Medicine, Kasturba Medical College, Manipal University, Madhav Nagar, Manipal, India.
Chiranjay MukhopadhyayDepartment of Microbiology, Kasturba Medical College, Manipal University, Madhav Nagar, Manipal, India.
Kasturba Medical College, Manipal · INManipal Academy of Higher Education · INNational Institute of Malaria Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral reports of chloroquine treatment failure and resistance in Plasmodium vivax malaria from Southeast Asian countries have been published. Present study was undertaken to assess the efficacy of chloroquine-primaquine (CQ-PQ) combined regimen for the treatment of P. vivax malaria patients who were catered by the selected primary health centres (PHCs) of Udupi taluk, Udupi district, Karnataka, India.

methodFive PHCs were selected within Udupi taluk based on probability proportional to size. In-vivo therapeutic efficacy assessment of CQ (1500 mg over three days) plus PQ (210 mg over 14 days) regimen was carried out in accordance with the World Health Organization's protocol of 28 days follow-up among microscopically diagnosed monoinfection P. vivax cohort.

resultsIn total, 161 participants were recruited in the study of which, 155 (96.3%) participants completed till day 28 follow-up, fully complied with the treatment regimen and showed adequate clinical and parasitological response. Loss to follow up was noted with 5 (3.1%) participants and non-compliance with treatment regimen occurred with one participant (0.6%). Glucose-6-phosphate dehydrogenase deficiency (G6PDd, <30% of normal mean activity) was noted among 5 (3.1%) participants and one of them did develop PQ induced dark-brown urination which subsided after PQ discontinuation. G6PDd patients were treated with PQ 45 mg/week for eight weeks while PQ was discontinued in one case with G6PD 1.4 U/g Hb due to complaint of reddish-brown coloured urine by 48 hours of PQ initiation. Nested polymerase chain reaction test revealed 45 (28%) cases as mixed (vivax and falciparum) malaria.

conclusionsThe CQ-PQ combined regimen remains outstandingly effective to treat uncomplicated P. vivax malaria in Udupi taluk and thus it should continue as first line regimen. For all P. vivax cases, G6PD screening before PQ administration must be mandatory and made available in all PHCs.

Indexed as

AdultAntimalarialsChloroquineDrug Therapy, CombinationFemaleGlucosephosphate DehydrogenaseHumansIndiaMalaria, VivaxMaleMiddle AgedPlasmodium vivaxPrimaquinePrimary Health CareAntimalarialsChloroquineglucose-6-phosphate dehydrogenase A-Glucosephosphate DehydrogenasePrimaquine

Identifiers

PMID27315280
PMCPMC4912090
OpenAlexW2429713299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.